These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Venular degeneration leads to vascular dysfunction in a transgenic model of Alzheimer's disease. Lai AY; Dorr A; Thomason LA; Koletar MM; Sled JG; Stefanovic B; McLaurin J Brain; 2015 Apr; 138(Pt 4):1046-58. PubMed ID: 25688079 [TBL] [Abstract][Full Text] [Related]
3. Simvastatin improves cerebrovascular function and counters soluble amyloid-beta, inflammation and oxidative stress in aged APP mice. Tong XK; Nicolakakis N; Fernandes P; Ongali B; Brouillette J; Quirion R; Hamel E Neurobiol Dis; 2009 Sep; 35(3):406-14. PubMed ID: 19524673 [TBL] [Abstract][Full Text] [Related]
4. Amyloid-β-dependent compromise of microvascular structure and function in a model of Alzheimer's disease. Dorr A; Sahota B; Chinta LV; Brown ME; Lai AY; Ma K; Hawkes CA; McLaurin J; Stefanovic B Brain; 2012 Oct; 135(Pt 10):3039-50. PubMed ID: 23065792 [TBL] [Abstract][Full Text] [Related]
5. Myeloid differentiation factor 88-deficient bone marrow cells improve Alzheimer's disease-related symptoms and pathology. Hao W; Liu Y; Liu S; Walter S; Grimm MO; Kiliaan AJ; Penke B; Hartmann T; Rübe CE; Menger MD; Fassbender K Brain; 2011 Jan; 134(Pt 1):278-92. PubMed ID: 21115468 [TBL] [Abstract][Full Text] [Related]
6. Concomitant detection of beta-amyloid peptides with N-terminal truncation and different C-terminal endings in cortical plaques from cases with Alzheimer's disease, senile monkeys and triple transgenic mice. Härtig W; Goldhammer S; Bauer U; Wegner F; Wirths O; Bayer TA; Grosche J J Chem Neuroanat; 2010 Sep; 40(1):82-92. PubMed ID: 20347032 [TBL] [Abstract][Full Text] [Related]
7. Does oxybutynin alter plaques, amyloid beta peptides and behavior in a mouse model of Alzheimer's disease? Klausner AP; Sharma S; Fletcher S; Neff P; Yang SK; Son H; Tuttle JB; Steers WD J Urol; 2008 Mar; 179(3):1173-7. PubMed ID: 18206173 [TBL] [Abstract][Full Text] [Related]
9. Immunomodulation of AβPP processing alleviates amyloid-β-related pathology in Alzheimer's disease transgenic mice. Arbel-Ornath M; Becker M; Rabinovich-Toidman P; Gartner M; Solomon B J Alzheimers Dis; 2010; 22(2):469-82. PubMed ID: 20847413 [TBL] [Abstract][Full Text] [Related]
10. Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Herzig MC; Winkler DT; Burgermeister P; Pfeifer M; Kohler E; Schmidt SD; Danner S; Abramowski D; Stürchler-Pierrat C; Bürki K; van Duinen SG; Maat-Schieman ML; Staufenbiel M; Mathews PM; Jucker M Nat Neurosci; 2004 Sep; 7(9):954-60. PubMed ID: 15311281 [TBL] [Abstract][Full Text] [Related]
11. [Production and catabolism of amyloid peptides in Alzheimer's disease]. Checler F Therapie; 2010; 65(5):409-14. PubMed ID: 21144475 [TBL] [Abstract][Full Text] [Related]
12. Current insights into molecular mechanisms of Alzheimer disease and their implications for therapeutic approaches. Van Broeck B; Van Broeckhoven C; Kumar-Singh S Neurodegener Dis; 2007; 4(5):349-65. PubMed ID: 17622778 [TBL] [Abstract][Full Text] [Related]
13. Design and evaluation of a 6-mer amyloid-beta protein derived phage display library for molecular targeting of amyloid plaques in Alzheimer's disease: Comparison with two cyclic heptapeptides derived from a randomized phage display library. Larbanoix L; Burtea C; Ansciaux E; Laurent S; Mahieu I; Vander Elst L; Muller RN Peptides; 2011 Jun; 32(6):1232-43. PubMed ID: 21575663 [TBL] [Abstract][Full Text] [Related]
14. Astrocytic expression of the Alzheimer's disease beta-secretase (BACE1) is stimulus-dependent. Hartlage-Rübsamen M; Zeitschel U; Apelt J; Gärtner U; Franke H; Stahl T; Günther A; Schliebs R; Penkowa M; Bigl V; Rossner S Glia; 2003 Jan; 41(2):169-79. PubMed ID: 12509807 [TBL] [Abstract][Full Text] [Related]
15. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Boche D; Zotova E; Weller RO; Love S; Neal JW; Pickering RM; Wilkinson D; Holmes C; Nicoll JA Brain; 2008 Dec; 131(Pt 12):3299-310. PubMed ID: 18953056 [TBL] [Abstract][Full Text] [Related]
16. Cerebral amyloid angiopathy: major contributor or decorative response to Alzheimer's disease pathogenesis. Castellani RJ; Smith MA; Perry G; Friedland RP Neurobiol Aging; 2004; 25(5):599-602; discussion 603-4. PubMed ID: 15172735 [TBL] [Abstract][Full Text] [Related]
17. A decade of modeling Alzheimer's disease in transgenic mice. McGowan E; Eriksen J; Hutton M Trends Genet; 2006 May; 22(5):281-9. PubMed ID: 16567017 [TBL] [Abstract][Full Text] [Related]
18. Stereological analysis of microvascular parameters in a double transgenic model of Alzheimer's disease. Lee GD; Aruna JH; Barrett PM; Lei DL; Ingram DK; Mouton PR Brain Res Bull; 2005 Apr; 65(4):317-22. PubMed ID: 15811597 [TBL] [Abstract][Full Text] [Related]
19. The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice. Lee JY; Friedman JE; Angel I; Kozak A; Koh JY Neurobiol Aging; 2004; 25(10):1315-21. PubMed ID: 15465629 [TBL] [Abstract][Full Text] [Related]
20. [Molecular actors in Alzheimer's disease: which diagnostic and therapeutic consequences?]. Buée L; Blum D; Bombois S; Buée-Scherrer V; Caillet-Boudin ML; Colin M; Deramecourt V; Dhaenens CM; Galas MC; Hamdane M; Humez S; Maurage CA; Pasquier F; Sablonnière B; Schraen-Maschke S; Sergeant N Therapie; 2010; 65(5):401-7. PubMed ID: 21144474 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]